Clinical trial · Observational
Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma
Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma Based on Tumor Immune Microenvironment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2\~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma (NPC) | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Study Groups
- interventionNames
- Other: No Intervention
Primary outcomes (1)
- measure
- Failure-free survival (FFS)
- timeFrame
- 3-year
- description
- Failure-free survival is measured from day of diagnosis until treatment failure, death from any cause, or last follow-up visit, whichever occurred first
Secondary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- 5-year
- description
- Overall survival is measured from day of diagnosis until death due to any cause or the latest known date alive
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria Before the trial, the participants must meet all of the following requirements to be eligible for inclusion. 1. Clearly diagnosed with nasopharyngeal carcinoma by pathology; 2. Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital; 3. Patients diagnosed in our hospital from January 2025 to December 2028; 4. Have relatively complete clinical data; 5. Age between 15 and 75 years old; Exclusion Criteria Before the trial, the participants who meet any of the following requirements cannot be included. 1. The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.; 2. The participants failed to obtain pathological and imaging data for various reasons; 3. Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.
References
Publications (0)
Data not yet available